James M. McCabe
YOU?
Author Swipe
View article: Protamine Utilization and Clinical Outcomes for Coronary Artery Perforation in Chronic Total Occlusion Percutaneous Coronary Intervention Procedures
Protamine Utilization and Clinical Outcomes for Coronary Artery Perforation in Chronic Total Occlusion Percutaneous Coronary Intervention Procedures Open
In this retrospective analysis, use of protamine in patients with coronary artery perforation complicating CTO PCI was associated with a reduction in death and cardiac tamponade without evidence of increased stent thrombosis. Additional st…
View article: Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial Open
Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy v…
View article: Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States
Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States Open
This large, real-world analysis confirms the safety and durability of AViV compared with TAVR at all surgical risk levels at mid-term follow-up. Consideration may be given to broadening the indication for AViV.
View article: Novel Use of MitraClip for Treatment of Severe Aortic Regurgitation
Novel Use of MitraClip for Treatment of Severe Aortic Regurgitation Open
A 33-year-old man with unrepaired tetralogy of Fallot, Eisenmenger syndrome, and torrential aortic regurgitation secondary to previous Streptococcus mitis endocarditis (now sterilized) presented to a local hospital with recurrent decompens…
View article: Transcatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC)
Transcatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC) Open
BACKGROUND: Mitral annular calcification with valve dysfunction remains a challenging syndrome. Operative risk is high, and available transcatheter therapies are limited. METHODS: This study describes our initial experience with a novel pr…
View article: Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expandable Aortic Transcatheter Valves in the U.S.
Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expandable Aortic Transcatheter Valves in the U.S. Open
MViR with third-generation balloon-expandable aortic transcatheter heart valves is associated with a significant reduction in mitral regurgitation and improvement in symptoms at 1 year, but with elevated valvular gradients and a high reint…
View article: Novel Use of a Left Atrial Appendage Occluder for Paravalvular Leak Closure
Novel Use of a Left Atrial Appendage Occluder for Paravalvular Leak Closure Open
Prosthetic valve paravalvular leak (PVL) can result in hemolytic anemia and heart failure.1 Successful PVL closure can reduce mortality.2 While surgical correction has been the historical gold standard for significant PVL, catheter-based P…
View article: Novel Transcatheter Approach to Treat Primum Atrial Septal Defects
Novel Transcatheter Approach to Treat Primum Atrial Septal Defects Open
•Degenerative common AVC defect can mimic rheumatic MV stenosis.•Closure of primum ASD can be achieved percutaneously.•Live 3D multiplanar TEE is crucial for procedural guidance.
View article: Transcatheter Aortic Valve-in-Valve Implantation within a Radiolucent Stentless Valve
Transcatheter Aortic Valve-in-Valve Implantation within a Radiolucent Stentless Valve Open
An 84-year-old man with a Shelhigh Super Stentless valve presented for valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR). Given the lack of radiopaque markers and the presence of a non-coronary cusp (NCC) pseudoaneurysm, i…
View article: Balloon‐assisted leaflet modification: Gaining momentum with innovative approaches
Balloon‐assisted leaflet modification: Gaining momentum with innovative approaches Open
Key Points Transcatheter mitral valve replacement (TMVR) is expanding. The risk of left ventricular outflow tract obstruction (LVOTO) remains a challenge. Balloon‐assisted leaflet modification is a reasonable approach to mitigate LVOTO, es…
View article: Supplementary Figure 2 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Figure 2 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody Open
Supplementary Figure 2 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
View article: Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody Open
Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
View article: Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody Open
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
View article: Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody Open
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody